Eli Lilly to Withdraw Insulin Basaglar from Indian Market; Product No Longer Profitable, Say Experts

An Eli Lilly spokesperson told News18 that the Basaglar KwikPen is being discontinued to streamline the pharma giant’s product portfolio in India. A company source and several experts, however, say tough competition and the price imposed by the NPPA has made the product financially unviable

from Top India News- News18.com https://ift.tt/5QrAI3O